Orion Portfolio Solutions LLC Boosts Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Orion Portfolio Solutions LLC increased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 36.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 30,625 shares of the specialty pharmaceutical company’s stock after acquiring an additional 8,235 shares during the period. Orion Portfolio Solutions LLC owned approximately 0.05% of Jazz Pharmaceuticals worth $3,771,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Townsquare Capital LLC purchased a new position in shares of Jazz Pharmaceuticals in the 3rd quarter valued at about $220,000. Fiduciary Trust Co increased its holdings in Jazz Pharmaceuticals by 49.6% in the third quarter. Fiduciary Trust Co now owns 6,770 shares of the specialty pharmaceutical company’s stock valued at $754,000 after buying an additional 2,246 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Jazz Pharmaceuticals by 17.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,899 shares of the specialty pharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 1,729 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after acquiring an additional 100,112 shares in the last quarter. Finally, Vinva Investment Management Ltd acquired a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $177,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $122.92 on Monday. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company’s 50 day simple moving average is $132.30 and its 200 day simple moving average is $122.66. The stock has a market capitalization of $7.47 billion, a PE ratio of 17.31, a P/E/G ratio of 1.04 and a beta of 0.44.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Robert Iannone sold 7,080 shares of the company’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at $11,368,526.40. This represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock worth $4,022,825 in the last quarter. 4.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on JAZZ shares. Barclays reaffirmed an “overweight” rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Morgan Stanley reiterated an “overweight” rating and issued a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Truist Financial raised their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Finally, Piper Sandler reissued an “overweight” rating and set a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Buy” and an average target price of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.